- Molecular NameSibutramine
- SynonymSibutramina [Spanish]; Sibutraminum [Latin]
- Weight279.855
- Drugbank_IDDB01105
- ACS_NO106650-56-0
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)4.93
- pka8.5
- LogD (pH=7, predicted)3.32
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.89
- LogSw (predicted, AB/LogsW2.0)0.03
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors0
- No.of HBond Acceptors1
- No.of Rotatable Bonds5
- TPSA3.24
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn orally administered agent for the treatment of obesity, as an appetite suppressant. It is a centrally-acting serotonin-norepinephrine reuptake inhibitor structurally related to amphetamines,
- Absorption_value77.0
- Absorption (description)Sibutramine is well absorbed from the GI tract (77%)
- Caco_2N/A
- BioavailabilityN/A
- Protein binding97.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (CYP3A4-mediated). Undergoes considerable first-pass metabolism, reducing its bioavailability. The drug itself reaches its peak plasma level after 1 hour and has also a half-life of 1 hour. Sibutramine is metabolized by cytochrome P450 isozyme CYP3A4 into two pharmacologically-active primary and secondary amines (called active metabolites 1 and 2) with half-lives of 14 and 16 hours, respectively. Peak plasma concentrations of active metabolites 1 and 2 are reached after three to four hours. The following metabolic pathway mainly results in two inactive conjugated and hydroxylated metabolites (called metabolites 5 and 6).
- Half lifesibutramine approx. 1 hour, Metabolite 1: 14 hours, Metabolite 2: 16 hours
- ExcretionBiliary (sibutramine and active metabolites), renal (inactive metabolites)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySide effects include dry mouth, anorexia, insomnia, constipation and headache.
- LD50 (rat)N/A
- LD50 (mouse)N/A